FDA Risk-Based Part 11 Proposal Expected By February 2003
This article was originally published in The Tan Sheet
Executive Summary
FDA intends to issue a policy statement on how its risk-based Good Manufacturing Practices initiative will affect 21 CFR Part 11 - the electronic records and electronic signatures reg - by early next year
You may also be interested in...
Critical Control Point Model In PAT Guidance Supported By Industry
FDA should adopt a critical control point model requiring firms only maintain data that pertain to significant manufacturing stages when drafting its Process Analytical Technology guidance, industry reps suggest
Critical Control Point Model In PAT Guidance Supported By Industry
FDA should adopt a critical control point model requiring firms only maintain data that pertain to significant manufacturing stages when drafting its Process Analytical Technology guidance, industry reps suggest
Critical Control Point Model In PAT Guidance Supported By Industry
FDA should adopt a critical control point model requiring firms only maintain data that pertain to significant manufacturing stages when drafting its Process Analytical Technology guidance, industry reps suggest